-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Initiates Coverage On Apogee Therapeutics with Overweight Rating, Announces Price Target of $95

Benzinga·12/17/2025 13:32:22
Listen to the news
Stephens & Co. analyst Sudan Loganathan initiates coverage on Apogee Therapeutics (NASDAQ:APGE) with a Overweight rating and announces Price Target of $95.